Universität zu Köln

Gause, A. M. and Rubbert-Roth, A. (2014). Recommendations on the use of rituximab for ANCA-associated vasculitis. Z. Rheumatol., 73 (3). S. 287 - 290. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1435-1250

Full text not available from this repository.

Abstract

Rituximab (Rtx) has been approved in Germany since April 2013 for treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). This therapy can be used in severe manifestations of these diseases and in relapses. It is administered as infusions of 375 mg rituximab per m(2) every 4 weeks after high dose intravenous prednisolone for 3 days and continued parallel to concomitant oral prednisolone therapy. Recommendations for the indications and use for antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) are described in addition to previous publications on recommendations for rheumatoid arthritis.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gause, A. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rubbert-Roth, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-441572
DOI:	10.1007/s00393-013-1318-3
Journal or Publication Title:	Z. Rheumatol.
Volume:	73
Number:	3
Page Range:	S. 287 - 290
Date:	2014
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1435-1250
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language WEGENERS-GRANULOMATOSIS; REMISSION-INDUCTION; CYCLOPHOSPHAMIDE; MAINTENANCE; BLADDER; CANCER Multiple languages Rheumatology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/44157